Article and Video CATEGORIES
Dr. Greg Riely: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.